Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC).

Allyson J. Ocean,Michael J. Guarino,K. Pennington,Bert H. O'Neil,C. S. Rocha Lima,Tanios Bekaii-Saab,Seza A. Gulec,David V. Gold,William A. Wegener,David M. Goldenberg

Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC).

2010

Allyson J. Ocean
Michael J. Guarino
K. Pennington
Bert H. O'Neil
C. S. Rocha Lima
Tanios Bekaii-Saab
Seza A. Gulec
David V. Gold
William A. Wegener
David M. Goldenberg

4115 Background: Since a single dose of 90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), showed transient objective antitumor activity in APC, we are evaluating repeated t...

Keywords:

Tetraxetan
Clivatuzumab
Therapeutic effect
Pancreatic cancer
Gemcitabine
Oncology
Internal medicine
Radioimmunotherapy
Medicine
Monoclonal antibody
low dose

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations